AI illustration · not actual product photoDetails from the source.
Source-listed Cagrilintide (SKU CGL10): 10mg*10vials. PriceList(1).pdf lists 183 per 10 vials but does not specify currency; the website displays $183 per 10 vials in USD per owner instruction. The source row does not establish the supplier-specific item's identity, lot quality, or approval.
- Catalogue code
- CGL10
- Source specification
- 10mg*10vials
- Source document
- PriceList(1).pdf, page 4
- Photograph
- AI-generated illustration only — not an actual product photo or verified molecular depiction; owner-approved product photo still pending.
Product information is presented from supplied source materials. Inclusion on this website does not state that a product is an approved medicine or authorize human use. This is educational content, not medical advice.
Compound-level research and safety context.
Evidence below concerns the research family associated with this listing. For blends, findings about individual components do not establish evidence for the combination. This does not verify the supplier-specific vial or lot. Reviewed 2026-10-30.
What it is
Peptide: cagrilintide is a long-acting synthetic amylin analogue. Catalogue details copied from the supplied PriceList(1).pdf: source SKU CGL5, *10 vials, 101 per 10 vials; source SKU CGL10, *10vials, 183 per 10 vials. Currency is not stated. The supplier-specific vial identity, formulation source, manufacturer, and batch are not verified.
Biological mechanism
Cagrilintide is an amylin analogue. Amylin receptor complexes include the calcitonin receptor with receptor activity-modifying proteins; cagrilintide’s effects are understood to involve amylin-related receptor signaling that can influence appetite and food intake. A mouse study found body-weight effects depended on AMY1 and AMY3 receptors, but this is preclinical and does not establish the mechanism in humans or in the catalogue vials. [3]
Research focus
Clinical research has investigated cagrilintide for weight management in adults with overweight or obesity. Research also examines amylin-receptor biology and food-intake pathways. Cagrilintide has additionally been studied in combination with semaglutide as CagriSema, a distinct intervention whose findings should not be attributed to standalone cagrilintide. [2] [3] [4]
Potential applications in the evidence
Weight management in adults with overweight or obesity is the application investigated in published clinical studies. These studies do not establish an approved use for the catalogue products, and no treatment claim or efficacy prediction for either exact vial is supported. [2]
Human evidence
A randomized, double-blind, 26-week phase 2 trial investigated standalone cagrilintide in adults with overweight or obesity. Under the trial-product estimand, reported mean weight reductions across cagrilintide groups were 6.0%–10.8%, compared with 3.0% for placebo. This establishes short-term clinical-trial evidence for the trial product, not long-term outcomes or performance of the supplier-specific vials. CagriSema studies concern cagrilintide plus semaglutide and are not evidence for the standalone catalogue item. [2] [4]
Known and potential effects
In the phase 2 trial, the most frequent adverse events were gastrointestinal disorders, including nausea, constipation and diarrhea, and administration-site reactions. Gastrointestinal events were reported in 41%–63% of cagrilintide recipients versus 32% with placebo; nausea in 20%–47% versus 18%. Trial data do not define risks for an unverified catalogue vial. [2]
Safety and contraindications
There is no cagrilintide-approved product label in the cited sources to establish contraindications for these catalogue entries. Their contents, identity, sterility, quality, storage characteristics, and formulation cannot be verified from the price list. FDA states cagrilintide cannot be used in compounding under federal law; do not infer that the supplier-specific vials are compounded or research-only without product-specific documentation. [1]
U.S. FDA / regulatory status
As of 2026-10-30, FDA’s communication current October 1, 2026 states cagrilintide is not a component of an FDA-approved drug, has not been found safe and effective for any condition, and cannot be used in compounding under federal law. This active-ingredient status is not proof about the manufacturer, formulation, jurisdiction, or regulatory status of either exact supplier-specific vial; those details are absent from the supplied catalogue. [1]
Evidence limitations
Standalone human evidence cited here includes a 26-week phase 2 trial, which does not establish long-term safety, durability of effect, or health outcomes beyond the trial. The receptor-mechanism source is a mouse study, not human mechanistic evidence. Combination-trial results cannot be transferred to standalone cagrilintide. The source catalogue identifies only labels, SKUs, listed strengths, and prices; it does not verify vial contents, manufacturer, batch, formulation source, or authorization. [1] [2] [3] [4]
Supporting sources
- FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss U.S. Food and Drug Administration · Regulatory safety communication. Supports: FDA statements on cagrilintide’s status, compounding restrictions, and absence from FDA-approved drugs.
- Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial The Lancet (indexed in PubMed) · Peer-reviewed randomized phase 2 human trial. Supports: Standalone trial design, weight outcomes, and reported adverse events.
- Cagrilintide lowers bodyweight through brain amylin receptors 1 and 3 EBioMedicine (indexed in PubMed) · Peer-reviewed preclinical mouse study. Supports: Amylin receptor context and animal findings concerning AMY1/AMY3 receptor dependence; not human evidence.
- Cagrilintide-Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes The New England Journal of Medicine (indexed in PubMed) · Peer-reviewed randomized phase 3 human trial of a combination. Supports: Clinical evidence for the cagrilintide-semiglutide combination, which must remain distinct from standalone cagrilintide.